Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 40.8% in March

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 41,900 shares, a decrease of 40.8% from the March 15th total of 70,800 shares. Approximately 2.6% of the company’s shares are short sold. Based on an average daily trading volume, of 1,820,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.39% of Cyclerion Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ CYCN traded up $0.07 during mid-day trading on Thursday, hitting $2.75. The company’s stock had a trading volume of 2,645 shares, compared to its average volume of 1,305,577. Cyclerion Therapeutics has a one year low of $1.27 and a one year high of $9.47. The company’s fifty day simple moving average is $2.71 and its 200-day simple moving average is $2.86. The stock has a market cap of $7.45 million, a price-to-earnings ratio of -2.25 and a beta of 1.96.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $1.81 million during the quarter.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.